Emergent BioSolutions repurchases USD 75 million of senior unsecured notes due 2028

• Emergent BioSolutions completed a repurchase of USD 75 million aggregate principal of its 3.875% Senior Unsecured Notes due 2028.
• Deployed about USD 68 million in cash; average repurchase price 90.6% of face value.
• Outstanding aggregate principal balance of the Senior Unsecured Notes reduced to about USD 364.7 million.
• Liquidity included a strong cash position; access to an additional USD 50 million under an asset-based revolving facility.
• Company evaluating timing to refinance remaining Senior Unsecured Notes maturing in August 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609030745PRIMZONEFULLFEED9820942) on September 03, 2026, and is solely responsible for the information contained therein.